研究性肽脱甲酰酶抑制剂NVP LBM-415与其他药物对人支原体和脲原体的体外活性比较
Comparative in vitro activities of investigational peptide deformylase inhibitor NVP LBM-415 and other agents against human mycoplasmas and ureaplasmas.
作者信息
Waites Ken B, Reddy Nipun B, Crabb Donna M, Duffy Lynn B
机构信息
Department of Pathology, WP 230, 619 19th Street South, Birmingham, AL 35249, USA.
出版信息
Antimicrob Agents Chemother. 2005 Jun;49(6):2541-2. doi: 10.1128/AAC.49.6.2541-2542.2005.
Abstract
Peptide deformylase inhibitor LBM-415 and seven other drugs were tested against Mycoplasma pneumoniae (100 isolates), Mycoplasma hominis (20 isolates), Mycoplasma fermentans (10 isolates), and Ureaplasma species (50 isolates). LBM-415 was active against M. pneumoniae (MICs, <or=0.008 microg/ml). It showed no activity against M. hominis and M. fermentans and modest activity against Ureaplasma spp.
摘要
肽脱甲酰基酶抑制剂LBM - 415以及其他七种药物针对肺炎支原体（100株分离株）、人型支原体（20株分离株）、发酵支原体（10株分离株）和解脲脲原体属（50株分离株）进行了测试。LBM - 415对肺炎支原体有活性（最低抑菌浓度，≤0.008微克/毫升）。它对人型支原体和发酵支原体无活性，对解脲脲原体属有适度活性。
相似文献
1
Comparative in vitro activities of investigational peptide deformylase inhibitor NVP LBM-415 and other agents against human mycoplasmas and ureaplasmas.
Antimicrob Agents Chemother. 2005 Jun;49(6):2541-2. doi: 10.1128/AAC.49.6.2541-2542.2005.
2
Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Antimicrob Agents Chemother. 2008 Oct;52(10):3776-8. doi: 10.1128/AAC.00849-08. Epub 2008 Jul 28.
3
Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Antimicrob Agents Chemother. 2003 Dec;47(12):3973-5. doi: 10.1128/AAC.47.12.3973-3975.2003.
4
Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.
Antimicrob Agents Chemother. 2009 May;53(5):2139-41. doi: 10.1128/AAC.00090-09. Epub 2009 Mar 2.
5
Activities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents against Mycoplasmas and Ureaplasmas in Humans, Including Isolates with Defined Resistance Mechanisms.
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01348-18. Print 2018 Nov.
6
Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas.
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.01064-17. Print 2017 Oct.
7
8
In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Antimicrob Agents Chemother. 2003 Jan;47(1):161-5. doi: 10.1128/AAC.47.1.161-165.2003.
9
In Vitro Activities of Omadacycline (PTK 0796) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas.
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7502-7504. doi: 10.1128/AAC.01734-16. Print 2016 Dec.
10
In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.
Antimicrob Agents Chemother. 2003 Jan;47(1):39-42. doi: 10.1128/AAC.47.1.39-42.2003.
引用本文的文献
1
Metal utilization in genome-reduced bacteria: Do human mycoplasmas rely on iron?
Comput Struct Biotechnol J. 2021 Oct 18;19:5752-5761. doi: 10.1016/j.csbj.2021.10.022. eCollection 2021.
2
Drug forecast - the peptide deformylase inhibitors as antibacterial agents.
Ther Clin Risk Manag. 2007 Aug;3(4):513-25.
3
Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US.
Drugs. 2007;67(5):773-92. doi: 10.2165/00003495-200767050-00010.
4
Activity of LBM415 compared to those of 11 other agents against Haemophilus species.
Antimicrob Agents Chemother. 2006 Jul;50(7):2323-9. doi: 10.1128/AAC.00106-06.
本文引用的文献
1
The genome sequence of Mycoplasma hyopneumoniae strain 232, the agent of swine mycoplasmosis.
J Bacteriol. 2004 Nov;186(21):7123-33. doi: 10.1128/JB.186.21.7123-7133.2004.
2
Mycoplasma pneumoniae and its role as a human pathogen.
Clin Microbiol Rev. 2004 Oct;17(4):697-728, table of contents. doi: 10.1128/CMR.17.4.697-728.2004.
3
Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
Antimicrob Agents Chemother. 2004 Oct;48(10):4033-6. doi: 10.1128/AAC.48.10.4033-4036.2004.
4
Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.
J Antimicrob Chemother. 2004 May;53(5):804-7. doi: 10.1093/jac/dkh184. Epub 2004 Mar 31.
5
Disk diffusion quality control guidelines for NVP-PDF 713: a novel peptide deformylase inhibitor.
Diagn Microbiol Infect Dis. 2004 Jan;48(1):55-7. doi: 10.1016/S0732-8893(03)00162-7.
6
Resistance to anti-peptide deformylase drugs.
Expert Opin Ther Targets. 2001 Jun;5(3):415-418. doi: 10.1517/14728222.5.3.415.
7
In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Antimicrob Agents Chemother. 2003 Jan;47(1):161-5. doi: 10.1128/AAC.47.1.161-165.2003.
8
Peptide deformylase as an antibacterial drug target: target validation and resistance development.
Antimicrob Agents Chemother. 2001 Apr;45(4):1058-64. doi: 10.1128/AAC.45.4.1058-1064.2001.
9
The complete sequence of the mucosal pathogen Ureaplasma urealyticum.
Nature. 2000 Oct 12;407(6805):757-62. doi: 10.1038/35037619.
10
Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents.
Mol Microbiol. 2000 Jun;36(6):1197-205. doi: 10.1046/j.1365-2958.2000.01908.x.
Zotero 插件